CAJ | 학술논문

目的：观察FOLFOX4方案联合肝动脉化疗栓塞术( TACE)治疗不能手术的结直肠癌肝转移患者的疗效及不良反应。方法收集已经临床明确诊断不能手术的结直肠癌肝转移患者42例,依据治疗方案分为FOLFOX4方案组(化疗组,n=20)及FOLFOX4+TACE组(联合组,n=22)：联合组接受FOLFOX4方案化疗3周期后行TACE治疗1次,每6周评价疗效。以RECIST1．1标准评价近期疗效,以NCI CTC3．0评价毒性反应。结果42例患者均可评价近期疗效和毒副反应。化疗组与联合组的客观有效率( RR )分别为25．0%(5/20)和40．9%(9/22),疾病控制率( DCR )分别为60．0%(12/20)和77．3%(17/22)。两组间RR和DCR的差异无统计学意义(P>0．05)。联合组的腹痛、肝功能损害、发热的发生率高于化疗组,差异有统计学意义(P<0．05)。结论 FOLFOX4方案联合TACE治疗不能手术切除结直肠癌肝转移具有一定的疗效,毒副反应可以耐受,安全性好,值得临床进一步研究。
목적：관찰FOLFOX4방안연합간동맥화료전새술( TACE)치료불능수술적결직장암간전이환자적료효급불량반응。방법수집이경림상명학진단불능수술적결직장암간전이환자42례,의거치료방안분위FOLFOX4방안조(화료조,n=20)급FOLFOX4+TACE조(연합조,n=22)：연합조접수FOLFOX4방안화료3주기후행TACE치료1차,매6주평개료효。이RECIST1．1표준평개근기료효,이NCI CTC3．0평개독성반응。결과42례환자균가평개근기료효화독부반응。화료조여연합조적객관유효솔( RR )분별위25．0%(5/20)화40．9%(9/22),질병공제솔( DCR )분별위60．0%(12/20)화77．3%(17/22)。량조간RR화DCR적차이무통계학의의(P>0．05)。연합조적복통、간공능손해、발열적발생솔고우화료조,차이유통계학의의(P<0．05)。결론 FOLFOX4방안연합TACE치료불능수술절제결직장암간전이구유일정적료효,독부반응가이내수,안전성호,치득림상진일보연구。
Objective To investigate the efficacy and side effects of FOLFOX4 regimen combined with transcatheter arte-rial chemoembolization( TACE) for the treatment of patients with hepatic metastases of inoperable colorectal cancer. Methods 42 patients with hepatic metastases of inoperable colorectal cancer were included. 20 of them received FOLFOX4 chemotherapy ( Chemo Group) . 22 of them received FOLFOX4 regimen combined with TACE ( Combined Group):TACE was performed once af-ter three cycles of FOLFOX4 chemotherapy. The efficacy were evaluated every 6 weeks. The short-time effect was evaluated by RECIST standard. The side effects were evaluated according to NCI CTC3. 0. Results RR was 25. 0% in Chemo Group and 40. 9% in Combined Group. DCR was 60. 0% in Chemo Group and 77. 3% in Combined Group. There was no significant differ-ence between the two groups(P>0. 05). The side-effects including abdominal pain,hepatic dysfunction,and fever were much com-mon in Combined Group compared to Chemo Group ( P<0. 05 ) . Conclusion FOLFOX4 regimen combined with TACE for the treatment of patients with hepatic metastases of inoperable colorectal cancer is effective and safe,which is worth to be further stud-ied.